Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance

Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genom...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Computers in biology and medicine 2021-09, Vol.136, p.104705-104705, Article 104705
Hauptverfasser: Ismail, Saba, Shahid, Farah, Khan, Abbas, Bhatti, Sadia, Ahmad, Sajjad, Naz, Anam, Almatroudi, Ahmad, Tahir ul Qamar, Muhammad
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 104705
container_issue
container_start_page 104705
container_title Computers in biology and medicine
container_volume 136
creator Ismail, Saba
Shahid, Farah
Khan, Abbas
Bhatti, Sadia
Ahmad, Sajjad
Naz, Anam
Almatroudi, Ahmad
Tahir ul Qamar, Muhammad
description Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide. •Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response.
doi_str_mv 10.1016/j.compbiomed.2021.104705
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2557544881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010482521004996</els_id><sourcerecordid>2557544881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</originalsourceid><addsrcrecordid>eNqFkcGKFDEQhoMoOK6-Q8CLlx4rnaQ7c9RFd4WF9aB4DOlKujdDd9ImmVn2IXxnM7QgePFUUPXVT_31E0IZ7Bmw7v1xj3FZBx8XZ_cttKy2RQ_yGdkx1R8akFw8JzsABo1QrXxJXuV8BAABHHbk11cTmrNB9CEuHjM165qiwQda4qNJtjboKfizS9nMdAMdRROst6Y4aibjQy70x-09XZOPyZcnupryECcXchWhxtrkcqZTio8-THSa41ClTCi-Xl080jr2uZiA7jV5MZo5uzd_6hX5_vnTt-vb5u7-5sv1h7sGeX8ozSgl8hZHxsXYdQgDs53tBW-57AUi5wcYhn5UnZCdMrIDGAeDgK06DCAF41fk3aZbvf48uVz04jO6eTbBxVPWrZS9FEKpC_r2H_QYTynU6yrVg-CKg6qU2ihMMefkRl2fsZj0pBnoS076qP_mpC856S2nuvpxW3XV8Nm7pDN6V59hfXJYtI3-_yK_AXaxoyA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570438308</pqid></control><display><type>article</type><title>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</title><source>Elsevier ScienceDirect Journals</source><creator>Ismail, Saba ; Shahid, Farah ; Khan, Abbas ; Bhatti, Sadia ; Ahmad, Sajjad ; Naz, Anam ; Almatroudi, Ahmad ; Tahir ul Qamar, Muhammad</creator><creatorcontrib>Ismail, Saba ; Shahid, Farah ; Khan, Abbas ; Bhatti, Sadia ; Ahmad, Sajjad ; Naz, Anam ; Almatroudi, Ahmad ; Tahir ul Qamar, Muhammad</creatorcontrib><description>Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide. •Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response.</description><identifier>ISSN: 0010-4825</identifier><identifier>EISSN: 1879-0534</identifier><identifier>DOI: 10.1016/j.compbiomed.2021.104705</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Affinity ; Antibiotic resistance ; Antibiotics ; Antigens ; Antimicrobial agents ; Antimicrobial resistance ; Bacteria ; Bacterial infections ; Campylobacter ; Computational vaccinology ; Drb1 protein ; Drug resistance ; Epitopes ; Histocompatibility antigen HLA ; Homology ; Human populations ; Immunogenicity ; Localization ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; Molecular docking ; Molecular interactions ; Multi-drug resistance ; Multidrug resistance ; Nosocomial infections ; Pan-vaccinomics ; Pathogenesis ; Pathogens ; Population genetics ; Proteins ; Proteomics ; R&amp;D ; Research &amp; development ; Simulation ; Streptococcus infections ; TLR2 protein ; TLR3 protein ; TLR4 protein ; Toll-like receptors ; Vaccines ; Virulence ; WHO priority List ; β-defensin</subject><ispartof>Computers in biology and medicine, 2021-09, Vol.136, p.104705-104705, Article 104705</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</citedby><cites>FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</cites><orcidid>0000-0002-1491-6402 ; 0000-0002-6514-5417 ; 0000-0003-4832-4250</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0010482521004996$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Ismail, Saba</creatorcontrib><creatorcontrib>Shahid, Farah</creatorcontrib><creatorcontrib>Khan, Abbas</creatorcontrib><creatorcontrib>Bhatti, Sadia</creatorcontrib><creatorcontrib>Ahmad, Sajjad</creatorcontrib><creatorcontrib>Naz, Anam</creatorcontrib><creatorcontrib>Almatroudi, Ahmad</creatorcontrib><creatorcontrib>Tahir ul Qamar, Muhammad</creatorcontrib><title>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</title><title>Computers in biology and medicine</title><description>Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide. •Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response.</description><subject>Affinity</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Antigens</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Campylobacter</subject><subject>Computational vaccinology</subject><subject>Drb1 protein</subject><subject>Drug resistance</subject><subject>Epitopes</subject><subject>Histocompatibility antigen HLA</subject><subject>Homology</subject><subject>Human populations</subject><subject>Immunogenicity</subject><subject>Localization</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Molecular docking</subject><subject>Molecular interactions</subject><subject>Multi-drug resistance</subject><subject>Multidrug resistance</subject><subject>Nosocomial infections</subject><subject>Pan-vaccinomics</subject><subject>Pathogenesis</subject><subject>Pathogens</subject><subject>Population genetics</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Simulation</subject><subject>Streptococcus infections</subject><subject>TLR2 protein</subject><subject>TLR3 protein</subject><subject>TLR4 protein</subject><subject>Toll-like receptors</subject><subject>Vaccines</subject><subject>Virulence</subject><subject>WHO priority List</subject><subject>β-defensin</subject><issn>0010-4825</issn><issn>1879-0534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcGKFDEQhoMoOK6-Q8CLlx4rnaQ7c9RFd4WF9aB4DOlKujdDd9ImmVn2IXxnM7QgePFUUPXVT_31E0IZ7Bmw7v1xj3FZBx8XZ_cttKy2RQ_yGdkx1R8akFw8JzsABo1QrXxJXuV8BAABHHbk11cTmrNB9CEuHjM165qiwQda4qNJtjboKfizS9nMdAMdRROst6Y4aibjQy70x-09XZOPyZcnupryECcXchWhxtrkcqZTio8-THSa41ClTCi-Xl080jr2uZiA7jV5MZo5uzd_6hX5_vnTt-vb5u7-5sv1h7sGeX8ozSgl8hZHxsXYdQgDs53tBW-57AUi5wcYhn5UnZCdMrIDGAeDgK06DCAF41fk3aZbvf48uVz04jO6eTbBxVPWrZS9FEKpC_r2H_QYTynU6yrVg-CKg6qU2ihMMefkRl2fsZj0pBnoS076qP_mpC856S2nuvpxW3XV8Nm7pDN6V59hfXJYtI3-_yK_AXaxoyA</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Ismail, Saba</creator><creator>Shahid, Farah</creator><creator>Khan, Abbas</creator><creator>Bhatti, Sadia</creator><creator>Ahmad, Sajjad</creator><creator>Naz, Anam</creator><creator>Almatroudi, Ahmad</creator><creator>Tahir ul Qamar, Muhammad</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AL</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>JQ2</scope><scope>K7-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0N</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1491-6402</orcidid><orcidid>https://orcid.org/0000-0002-6514-5417</orcidid><orcidid>https://orcid.org/0000-0003-4832-4250</orcidid></search><sort><creationdate>202109</creationdate><title>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</title><author>Ismail, Saba ; Shahid, Farah ; Khan, Abbas ; Bhatti, Sadia ; Ahmad, Sajjad ; Naz, Anam ; Almatroudi, Ahmad ; Tahir ul Qamar, Muhammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Affinity</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Antigens</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Campylobacter</topic><topic>Computational vaccinology</topic><topic>Drb1 protein</topic><topic>Drug resistance</topic><topic>Epitopes</topic><topic>Histocompatibility antigen HLA</topic><topic>Homology</topic><topic>Human populations</topic><topic>Immunogenicity</topic><topic>Localization</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Molecular docking</topic><topic>Molecular interactions</topic><topic>Multi-drug resistance</topic><topic>Multidrug resistance</topic><topic>Nosocomial infections</topic><topic>Pan-vaccinomics</topic><topic>Pathogenesis</topic><topic>Pathogens</topic><topic>Population genetics</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Simulation</topic><topic>Streptococcus infections</topic><topic>TLR2 protein</topic><topic>TLR3 protein</topic><topic>TLR4 protein</topic><topic>Toll-like receptors</topic><topic>Vaccines</topic><topic>Virulence</topic><topic>WHO priority List</topic><topic>β-defensin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ismail, Saba</creatorcontrib><creatorcontrib>Shahid, Farah</creatorcontrib><creatorcontrib>Khan, Abbas</creatorcontrib><creatorcontrib>Bhatti, Sadia</creatorcontrib><creatorcontrib>Ahmad, Sajjad</creatorcontrib><creatorcontrib>Naz, Anam</creatorcontrib><creatorcontrib>Almatroudi, Ahmad</creatorcontrib><creatorcontrib>Tahir ul Qamar, Muhammad</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Computing Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Computer Science Collection</collection><collection>Computer Science Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Computing Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Computers in biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ismail, Saba</au><au>Shahid, Farah</au><au>Khan, Abbas</au><au>Bhatti, Sadia</au><au>Ahmad, Sajjad</au><au>Naz, Anam</au><au>Almatroudi, Ahmad</au><au>Tahir ul Qamar, Muhammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</atitle><jtitle>Computers in biology and medicine</jtitle><date>2021-09</date><risdate>2021</risdate><volume>136</volume><spage>104705</spage><epage>104705</epage><pages>104705-104705</pages><artnum>104705</artnum><issn>0010-4825</issn><eissn>1879-0534</eissn><abstract>Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide. •Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.compbiomed.2021.104705</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-1491-6402</orcidid><orcidid>https://orcid.org/0000-0002-6514-5417</orcidid><orcidid>https://orcid.org/0000-0003-4832-4250</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0010-4825
ispartof Computers in biology and medicine, 2021-09, Vol.136, p.104705-104705, Article 104705
issn 0010-4825
1879-0534
language eng
recordid cdi_proquest_miscellaneous_2557544881
source Elsevier ScienceDirect Journals
subjects Affinity
Antibiotic resistance
Antibiotics
Antigens
Antimicrobial agents
Antimicrobial resistance
Bacteria
Bacterial infections
Campylobacter
Computational vaccinology
Drb1 protein
Drug resistance
Epitopes
Histocompatibility antigen HLA
Homology
Human populations
Immunogenicity
Localization
Lymphocytes
Lymphocytes B
Lymphocytes T
Molecular docking
Molecular interactions
Multi-drug resistance
Multidrug resistance
Nosocomial infections
Pan-vaccinomics
Pathogenesis
Pathogens
Population genetics
Proteins
Proteomics
R&D
Research & development
Simulation
Streptococcus infections
TLR2 protein
TLR3 protein
TLR4 protein
Toll-like receptors
Vaccines
Virulence
WHO priority List
β-defensin
title Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A42%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pan-vaccinomics%20approach%20towards%20a%20universal%20vaccine%20candidate%20against%20WHO%20priority%20pathogens%20to%20address%20growing%20global%20antibiotic%20resistance&rft.jtitle=Computers%20in%20biology%20and%20medicine&rft.au=Ismail,%20Saba&rft.date=2021-09&rft.volume=136&rft.spage=104705&rft.epage=104705&rft.pages=104705-104705&rft.artnum=104705&rft.issn=0010-4825&rft.eissn=1879-0534&rft_id=info:doi/10.1016/j.compbiomed.2021.104705&rft_dat=%3Cproquest_cross%3E2557544881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570438308&rft_id=info:pmid/&rft_els_id=S0010482521004996&rfr_iscdi=true